Molecular Neurodegeneration

Article	Citations
LRP1: a novel receptor for the transmission of pathological α-Synuclein	258
Valosin containing protein (VCP): initiator, modifier, and potential drug target for neurodegenerative diseases	227
In Memoriam of John T. Trojanowski, MD, PhD 1946-2022	153
The informed road map to prevention of Alzheimer Disease: A call to arms	148
Regulation of cortical hyperexcitability in amyotrophic lateral sclerosis: focusing on glial mechanisms	148
Mitochondrial CISD1/Cisd accumulation blocks mitophagy and genetic or pharmacological inhibition rescues neurodegenerative phenotypes in Pink1/parkin models	142
Tau interactome and RNA binding proteins in neurodegenerative diseases	132
Fluid biomarkers for amyotrophic lateral sclerosis: a review	130
Nuclear import receptors are recruited by FG-nucleoporins to rescue hallmarks of TDP-43 proteinopathy	126
The TGFβ/Notch axis facilitates Müller cell-to-epithelial transition to ultimately form a chronic glial scar	122
AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma	120
A proteomic network approach resolves stage-specific molecular phenotypes in chronic traumatic encephalopathy	119
A microglial activity state biomarker panel differentiates FTD-granulin and Alzheimer’s disease patients from controls	115
Pharmacological rescue of cognitive function in a mouse model of chemobrain	114
Regulation of the hippocampal translatome by Apoer2-ICD release	113
Glial interference: impact of type I interferon in neurodegenerative diseases	112
Modulating innate immune activation states impacts the efficacy of specific Aβ immunotherapy	108
AIF3 splicing switch triggers neurodegeneration	101
Melatonin: a ferroptosis inhibitor with potential therapeutic efficacy for the post-COVID-19 trajectory of accelerated brain aging and neurodegeneration	100
An adapted protocol to derive microglia from stem cells and its application in the study of CSF1R-related disorders	99
Astrocytes of the optic nerve exhibit a region-specific and temporally distinct response to elevated intraocular pressure	95
News & views: anti-amyloid antibodies and novel emerging approaches to Alzheimer’s disease in 2023	90
Microglial CD2AP deficiency exerts protection in an Alzheimer’s disease model of amyloidosis	82
A Trem2R47H mouse model without cryptic splicing drives age- and disease-dependent tissue damage and synaptic loss in response to plaques	72
Cerebrospinal fluid lipoproteins inhibit α-synuclein aggregation by interacting with oligomeric species in seed amplification assays	70

A partial Drp1 knockout improves autophagy flux independent of mitochondrial function	70
Alzheimer’s disease: targeting the peripheral circulation	69
Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson’s disease brain	69
Unraveling the complex role of MAPT-containing H1 and H2 haplotypes in neurodegenerative diseases	67
Retinal ganglion cell repopulation for vision restoration in optic neuropathy: a roadmap from the RReSTORe Consortium	67
Amyloid-β specific regulatory T cells attenuate Alzheimer’s disease pathobiology in APP/PS1 mice	62
Optimizing detection of Alzheimer’s disease in mild cognitive impairment: a 4-year biomarker study of mild behavioral impairment in ADNI and MEMENTO	61
CSF proteins of inflammation, proteolysis and lipid transport define preclinical AD and progression to AD dementia in cognitively unimpaired individuals	61
Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia	60
Current views on meningeal lymphatics and immunity in aging and Alzheimer’s disease	58
Untargeted serum metabolomics reveals novel metabolite associations and disruptions in amino acid and lipid metabolism in Parkinson’s disease	57
The gut microbiome regulates astrocyte reaction to Aβ amyloidosis through microglial dependent and independent mechanisms	57
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies	56
Microglial TYROBP/DAP12 in Alzheimer’s disease: Transduction of physiological and pathological signals across TREM2	55
Positron emission tomography tracers for synucleinopathies	55
Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer’s disease: a systematic review of symptom-general and –specific lesion patterns	54
Specific detection of tau seeding activity in Alzheimer’s disease using rationally designed biosensor cells	53
TREM2 dependent and independent functions of microglia in Alzheimer’s disease	52
APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases	50
Common features of neurodegenerative disease: exploring the brain-eye connection and beyond (Part 1): the 2021 pre-symposium of the 15th international conference on Alzheimer’s and Parkinson’s disease	50
Opposing effects of apoE2 and apoE4 on microglial activation and lipid metabolism in response to demyelination	50
Guidelines for bioinformatics of single-cell sequencing data analysis in Alzheimer’s disease: review, recommendation, implementation and application	48
Leveraging the glymphatic and meningeal lymphatic systems as therapeutic strategies in Alzheimer’s disease: an updated overview of nonpharmacological therapies	48
Extracellular protein components of amyloid plaques and their roles in Alzheimer’s disease pathology	47
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications	45
Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer’s disease	44
High dose expression of heme oxigenase-1 induces retinal degeneration through ER stress-related DDIT3	43
TDP-43 pathology is associated with increased tau burdens and seeding	43
Challenge accepted: uncovering the role of rare genetic variants in Alzheimer’s disease	42
Correction to: Plaque associated microglia hyper-secrete extracellular vesicles and accelerate tau propagation in a humanized APP mouse model	41
A novel AAV Vector for gene therapy of RPE-related retinal degenerative diseases via intravitreal delivery	40
Whole-genome sequencing analysis reveals new susceptibility loci and structural variants associated with progressive supranuclear palsy	39
TREM2 and microglia exosomes: a potential highway for pathological tau	39
Targeted degradation of ⍺-synuclein aggregates in Parkinson’s disease using the AUTOTAC technology	39
Correction: Multi-modal proteomic characterization of lysosomal function and proteostasis in progranulin-deficient neurons	39
Drug development targeting degeneration of the basal forebrain cholinergic system: its time has come	37
Aging-associated sensory decline and Alzheimer’s disease	36
Emerging targets of α-synuclein spreading in α-synucleinopathies: a review of mechanistic pathways and interventions	36
Chitinase-3-like-1: a multifaceted player in neuroinflammation and degenerative pathologies with therapeutic implications	36
Mis-localization of endogenous TDP-43 leads to ALS-like early-stage metabolic dysfunction and progressive motor deficits	36
Brain clearance of protein aggregates: a close-up on astrocytes	35
Cellular stress signaling and the unfolded protein response in retinal degeneration: mechanisms and therapeutic implications	35
Astrocytic APOE4 removal confers cerebrovascular protection despite increased cerebral amyloid angiopathy	35
Impaired antioxidant KEAP1-NRF2 system in amyotrophic lateral sclerosis: NRF2 activation as a potential therapeutic strategy	34
Are oligodendrocytes the missing link in Alzheimer’s disease and related dementia research?	34
Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration	34
In memoriam of Huaxi Xu, PhD, 1964–2022	33
Common mouse models of tauopathy reflect early but not late human disease	33
Anti-acetylated-tau immunotherapy is neuroprotective in tauopathy and brain injury	33
Characterization of mitochondrial DNA quantity and quality in the human aged and Alzheimer’s disease brain	32

TDP-43 Pathology in Alzheimer’s Disease	32
Misfolded protein oligomers: mechanisms of formation, cytotoxic effects, and pharmacological approaches against protein misfolding diseases	30
CSF protein ratios with enhanced potential to reflect Alzheimer’s disease pathology and neurodegeneration	30
Rejuvenating aged microglia by p16ink4a-siRNA-loaded nanoparticles increases amyloid-β clearance in animal models of Alzheimer’s disease	29
Knock-in models related to Alzheimer’s disease: synaptic transmission, plaques and the role of microglia	29
Nuclear-import receptors as gatekeepers of pathological phase transitions in ALS/FTD	29
TDP-43-regulated cryptic RNAs accumulate in Alzheimer’s disease brains	29
Clarifying the association of CSF Aβ, tau, BACE1, and neurogranin with AT(N) stages in Alzheimer disease	28
One immune cell to bind them all: platelet contribution to neurodegenerative disease	27
VCP suppresses proteopathic seeding in neurons	26
Neuronal and glial vulnerability of the suprachiasmatic nucleus in tauopathies: evidence from human studies and animal models	25
Edaravone activates the GDNF/RET neurotrophic signaling pathway and protects mRNA-induced motor neurons from iPS cells	25
Collagen in the central nervous system: contributions to neurodegeneration and promise as a therapeutic target	25
Transcriptome deregulation of peripheral monocytes and whole blood in GBA-related Parkinson’s disease	25
α-Synuclein serine129 phosphorylation – the physiology of pathology	24
Parkinson mice show functional and molecular changes in the gut long before motoric disease onset	23
Global neuropathologic severity of Alzheimer’s disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels	23
Circadian clocks, cognition, and Alzheimer’s disease: synaptic mechanisms, signaling effectors, and chronotherapeutics	23
SETD7-mediated monomethylation is enriched on soluble Tau in Alzheimer’s disease	22
The Parkinson’s disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons	22
“Don’t Phos Over Tau”: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies	22
CX3CR1 deficiency aggravates amyloid driven neuronal pathology and cognitive decline in Alzheimer’s disease	22
The role of ATP-binding cassette subfamily A in the etiology of Alzheimer’s disease	21
TREM2/PLCγ2 signalling in immune cells: function, structural insight, and potential therapeutic modulation	21
The gut microbiome in Alzheimer’s disease: what we know and what remains to be explored	21
Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA	20
Sex specific molecular networks and key drivers of Alzheimer’s disease	20
Neuroprotection by WldS depends on retinal ganglion cell type and age in glaucoma	20
Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery	20
Correction: Predominant expression of Alzheimer’s disease-associated BIN1 in mature oligodendrocytes and localization to white matter tracts	20
Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions	20
A genome-wide search for pleiotropy in more than 100,000 harmonized longitudinal cognitive domain scores	20
Astrocytic autophagy plasticity modulates Aβ clearance and cognitive function in Alzheimer’s disease	20
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics	20
Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner	20
Correction: Alzheimer risk gene product Pyk2 suppresses tau phosphorylation and phenotypic effects of tauopathy	20
Human iPSC-derived astrocytes transplanted into the mouse brain undergo morphological changes in response to amyloid-β plaques	20
Comparing anti-tau antibodies under clinical trials and their epitopes on tau pathologies	20
Post-infection cognitive impairments in a cohort of elderly patients with COVID-19	20
Correction: Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer’s disease	20
Correction: Drug development targeting degeneration of the basal forebrain cholinergic system: its time has come	20
Correction to: New approaches to symptomatic treatments for Alzheimer’s disease	20
Microglial lactate metabolism as a potential therapeutic target for Alzheimer’s disease	20
Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress	19
hiPSC-based models to decipher the contribution of human astrocytes to Alzheimer’s disease and potential therapeutics	19
RETRACTED ARTICLE: Calcium-dependent cytosolic phospholipase A2 activation is implicated in neuroinflammation and oxidative stress associated with ApoE4	19
Farnesyltransferase inhibitor LNK-754 attenuates axonal dystrophy and reduces amyloid pathology in mice	18
Cognitive, functional, and neuropsychiatric correlates of regional tau pathology in autopsy-confirmed chronic traumatic encephalopathy	18
Sex dependent glial-specific changes in the chromatin accessibility landscape in late-onset Alzheimer’s disease brains	18
Increased serum QUIN/KYNA is a reliable biomarker of post-stroke cognitive decline	18
Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP	18
Mechanisms of ARIA: is it time to focus on the unique immune environment of the neurovascular unit?	17
Neuropathology and molecular diagnosis of Synucleinopathies	17
Opinion: more mouse models and more translation needed for ALS	17
Frontotemporal dementia-like disease progression elicited by seeded aggregation and spread of FUS	17
Measuring the cognitive costs of the COVID-19 pandemic	17
Single-domain antibody-based protein degrader for synucleinopathies	17
The role of NURR1 in metabolic abnormalities of Parkinson’s disease	17
Trem2 deletion enhances tau dispersion and pathology through microglia exosomes	16
Identification of sixteen novel candidate genes for late onset Parkinson’s disease	16
Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans	16
Accumulation of saposin in dystrophic neurites is linked to impaired lysosomal functions in Alzheimer’s disease brains	16
Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease	16
GBA1 inactivation in oligodendrocytes affects myelination and induces neurodegenerative hallmarks and lipid dyshomeostasis in mice	15
Regional desynchronization of microglial activity is associated with cognitive decline in Alzheimer’s disease	14
NF-κB is a critical mediator of post-mitotic senescence in oligodendrocytes and subsequent white matter loss	14
Peptide-based approaches to directly target alpha-synuclein in Parkinson’s disease	14
The Q/R editing site of AMPA receptor GluA2 subunit acts as an epigenetic switch regulating dendritic spines, neurodegeneration and cognitive deficits in Alzheimer’s disease	14
A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study	14
The Golgi apparatus: Site for convergence of COVID-19 brain fog and Alzheimer’s disease?	14
Wild-type FUS corrects ALS-like disease induced by cytoplasmic mutant FUS through autoregulation	14
VPS35 and α-Synuclein fail to interact to modulate neurodegeneration in rodent models of Parkinson’s disease	13
Elevated ganglioside GM2 activator (GM2A) in human brain tissue reduces neurite integrity and spontaneous neuronal activity	13
FUS-ALS hiPSC-derived astrocytes impair human motor units through both gain-of-toxicity and loss-of-support mechanisms	13
Multi-analyte proteomic analysis identifies blood-based neuroinflammation, cerebrovascular and synaptic biomarkers in preclinical Alzheimer’s disease	13
The concept of resilience to Alzheimer’s Disease: current definitions and cellular and molecular mechanisms	13
APOE effects on regional tau in preclinical Alzheimer’s disease	13
Fate-mapping and functional dissection reveal perilous influence of type I interferon signaling in mouse brain aging	13
Oleoylethanolamide facilitates PPARα and TFEB signaling and attenuates Aβ pathology in a mouse model of Alzheimer’s disease	12
SRSF1-dependent inhibition of C9ORF72-repeat RNA nuclear export: genome-wide mechanisms for neuroprotection in amyotrophic lateral sclerosis	12

Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories	12
Amyloid-β (Aβ) immunotherapy induced microhemorrhages are linked to vascular inflammation and cerebrovascular damage in a mouse model of Alzheimer’s disease	12
APOΕ4 lowers energy expenditure in females and impairs glucose oxidation by increasing flux through aerobic glycolysis	12
Single-cell peripheral immunoprofiling of Lewy body and Parkinson’s disease in a multi-site cohort	12
Correction: The Parkinson’s disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons	11
Correction: Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism	11
Unravelling cell type-specific responses to Parkinson’s Disease at single cell resolution	11
NOTCH2NLC GGC intermediate repeat with serine induces hypermyelination and early Parkinson’s disease-like phenotypes in mice	11
Human VCP mutant ALS/FTD microglia display immune and lysosomal phenotypes independently of GPNMB	11
Correction: Blood–brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism	11
Anti-amyloid therapies for Alzheimer disease: finally, good news for patients	11
Correction: Whole-genome sequencing analysis reveals new susceptibility loci and structural variants associated with progressive supranuclear palsy	11
Correction to: A pharmacological chaperone improves memory by reducing Aβ and tau neuropathology in a mouse model with plaques and tangles	10
Non-invasive systemic viral delivery of human alpha-synuclein mimics selective and progressive neuropathology of Parkinson’s disease in rodent brains	10
SIRT2 and ALDH1A1 as critical enzymes for astrocytic GABA production in Alzheimer’s disease	10
HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases	10
VCP regulates early tau seed amplification via specific cofactors	10
Altered network properties in C9ORF72 repeat expansion cortical neurons are due to synaptic dysfunction	10
LRP1 is a neuronal receptor for α-synuclein uptake and spread	10
The major TMEM106B dementia risk allele affects TMEM106B protein levels, fibril formation, and myelin lipid homeostasis in the ageing human hippocampus	10
Biophysical mapping of TREM2-ligand interactions reveals shared surfaces for engagement of multiple Alzheimer’s disease ligands	10
Anti-malaria drug artesunate prevents development of amyloid-β pathology in mice by upregulating PICALM at the blood-brain barrier	10
The role of peripheral inflammatory insults in Alzheimer’s disease: a review and research roadmap	10
BIN1 is a key regulator of proinflammatory and neurodegeneration-related activation in microglia	9
Microbial-derived metabolites as a risk factor of age-related cognitive decline and dementia	9
Increased expression of mesencephalic astrocyte-derived neurotrophic factor (MANF) contributes to synapse loss in Alzheimer’s disease	9
Single molecule array measures of LRRK2 kinase activity in serum link Parkinson’s disease severity to peripheral inflammation	9
A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis	9
The CD33 short isoform is a gain-of-function variant that enhances Aβ1–42 phagocytosis in microglia	9
Differential regulation of progranulin derived granulin peptides	9
Donald Lowell Price, M.D. In memoriam	9
Pathological characteristics of axons and alterations of proteomic and lipidomic profiles in midbrain dopaminergic neurodegeneration induced by WDR45-deficiency	8
APOE4 genotype and aging impair injury-induced microglial behavior in brain slices, including toward Aβ, through P2RY12	8
Heparin-enriched plasma proteome is significantly altered in Alzheimer’s disease	8
Vesicle trafficking and pathways to neurodegeneration	8
Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease	8
Proteomic analysis of APOEε4 carriers implicates lipid metabolism, complement and lymphocyte signaling in cognitive resilience	8
Alzheimer’s genes in microglia: a risk worth investigating	8
Repetitive transcranial magnetic stimulation alleviates motor impairment in Parkinson’s disease: association with peripheral inflammatory regulatory T-cells and SYT6	8